Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Chugai or Roche Products Ltd. Please see the contact details below or click here for more information.

Report an Adverse Reaction to Chugai Pharma UK Ltd
(for Grancoyte, Aloxi and Akynzeo)
Telephone: +44 (0) 20 8987 5600
Email: [email protected]

Report an Adverse Reaction to Roche Products Ltd
Email: [email protected]

Adverse events for Hemlibra and RoActemra should be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing Roche. As Hemlibra and RoActemra are biological medicines, healthcare professionals should report adverse reactions by brand name and batch number.

Roche are the marketing authorisation holders for Hemlibra and RoActemra and Chugai work closely in partnership with Roche to promote these medicines to prescribers. Helsinn are the marketing authorisation holders for Akynzeo and Aloxi and Chugai work closely in partnership with Helsinn to promote these medicines to prescribers.